
Dengue is a febrile illness caused by four distinct dengue viruses (DENV-1, DENV-2, DENV-3, and DENV-4). The virus is transmitted by infected Aedes mosquitoes (1). In 2025, several countries and territories in the Western Pacific Region experienced dengue outbreaks (2), and on June 20, 2025, American Samoa, a territory of the United States located in the south Pacific Ocean, reported its first positive dengue test result in 2025. Two weeks later, on July 8, American Samoa declared a public health emergency after identifying six dengue cases, including two locally acquired cases and four associated with travel to neighboring Samoa, where a large dengue outbreak was ongoing (3,4). Recent dengue outbreaks in American Samoa were associated with DENV-4 (2009), DENV-3 (2015), and DENV-2 (2016-2018) (5). After the 2016-2018 outbreak, American Samoa implemented confirmatory laboratory dengue testing on the island.
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that help regulate appetite, lower blood glucose levels, and promote weight loss. GLP-1 medications are approved by the Food and Drug Administration (FDA) for type 2 diabetes treatment, chronic weight management, and treatment of certain other health conditions. Data from CDC's Rapid Surveys System were used to examine GLP-1 medication use among U.S. adults. During July-August 2025, approximately one in 10 U.S. adults reported taking a GLP-1 medication during the past year. Among GLP-1 users, approximately one in five reported taking a compounded version. Compounded GLP-1 medications are not reviewed by FDA for safety, effectiveness, or quality before they are marketed. Approximately two in five GLP-1 users modified their use of the medication from the way it was prescribed, often citing cost and availability as barriers to prescribed use. Substantial prevalence of GLP-1 medication use highlights the expanded role of these medications in chronic disease pharmacotherapy. Modifications in medication use, particularly among younger adults, reflect, in part, responses to cost- and access-related challenges. Better understanding of real-world medication use, including dose and frequency adjustments, is important because it might have implications for safety and effectiveness.
Since 2017, syphilis cases have increased substantially across the United States, including in Alaska. Nationwide, prevalence of syphilis tends to be higher among incarcerated persons than among the general population. During 2023-2025, opt-out screening for syphilis in Alaska correctional facilities (i.e., routine testing unless a person specifically declines) found reactive rapid plasma reagin (RPR) results, which often indicate a past or current syphilis infection, in 240 (4.6%) of 5,163 persons screened. Among persons with reactive RPR results, 114 (47.5%) had newly identified syphilis cases (2.2% of all persons screened), based on the 2018 Council of State and Territorial Epidemiologists definition. Among persons with newly identified syphilis, 88 (77.2%) were known to have completed treatment by September 2025. Among 1,020 women incarcerated in Alaska who were screened (19.6% of all persons screened), 95 (9.3%) had reactive RPR results. Among those 95 persons, 37 (3.6% of women screened) had newly identified confirmed or probable syphilis, and the remaining 58 (5.7% of women screened) had positive treponemal test results, demonstrating a high current or past syphilis prevalence among women incarcerated in Alaska. Implementing opt-out screening and treatment in correctional facilities could improve syphilis detection and treatment among persons in correctional facilities, and thereby reduce community syphilis transmission and help prevent congenital syphilis.
Cutaneous aspergillosis is a rare, life-threatening fungal infection in neonates, particularly those born extremely preterm (gestational age <28 weeks); outbreaks have been linked to environmental sources of Aspergillus species. The Michigan Department of Health and Human Services and the New York State Department of Health investigated two clusters of cutaneous aspergillosis in neonatal intensive care units during 2023-2024. In Michigan, two extremely preterm neonates (gestational age <24 weeks) received a diagnosis of cutaneous aspergillosis. Samples cultured from both infants were positive for Aspergillus fumigatus; both received antifungal treatment, and one infant died. In New York, three neonates (two born at gestational age 24-25 weeks and one at <24 weeks) received a diagnosis of cutaneous aspergillosis. Isolates from skin lesions were identified as A. fumigatus (one isolate) and closely related Aspergillus quadrilineatus (two isolates); all infants received antifungal treatment, and all three survived. In Michigan, A. fumigatus was isolated from an air sample collected near linen-transport areas; environmental sampling was not performed in New York. No definitive environmental source was identified for either cluster. Both investigations led to targeted infection control interventions, including revised linen handling, optimized airflow and air-handling systems, and enhanced skin assessment and infection prevention practices. These clusters underscore the susceptibility of extremely preterm neonates to invasive mold infections and the importance of early recognition, thorough environmental assessment and multidisciplinary collaboration, to prevent further exposures.
Andes virus (ANDV), the only hantavirus known to be transmitted person-to-person, is endemic to areas of South America and can cause hantavirus pulmonary syndrome, which has a case-fatality rate of approximately 40%. On May 4, 2026, CDC was notified of seven cases of severe acute respiratory illness, including three deaths, among 147 persons aboard a cruise ship in the Atlantic Ocean; the illnesses were later confirmed to be caused by ANDV. No cases occurred among passengers who were U.S. residents. Ten of 28 U.S. resident passengers disembarked before ANDV infection was confirmed aboard the ship. On May 10, the remaining 18 U.S. resident passengers were repatriated to the National Quarantine Unit in Omaha, Nebraska, for risk assessment and monitoring, and where optimized advanced care was available, should symptoms develop. CDC and U.S. health departments monitored 60 additional U.S. residents potentially exposed on flights involving a passenger with symptomatic ANDV infection from the cruise, totaling 88 contacts across 27 jurisdictions. All 88 contacts completed 42 days of monitoring, with no secondary ANDV infections identified. Worldwide, local health authorities assessed and monitored approximately 653 potentially exposed persons from 33 countries. This response highlights the value of rapid coordination among partners to locate and monitor potentially exposed persons during an international outbreak to reduce the risk for ANDV transmission. Prompt notification to public health authorities can facilitate testing, patient care, contact identification, and implementation of measures to limit secondary transmission.